EMEA-001943-PIP05-21
Key facts
Invented name |
Ultomiris
|
Active substance |
ravulizumab
|
Therapeutic area |
Neurology
|
Decision number |
P/0413/2021
|
PIP number |
EMEA-001943-PIP05-21
|
Pharmaceutical form(s) |
Concentrate for solution for infusion
|
Condition(s) / indication(s) |
Treatment of amyotrophic lateral sclerosis
|
Route(s) of administration |
Intravenous use
|
Contact for public enquiries |
Alexion Europe SAS
E-mail: pip.enquiries.eu@alexion.com |
Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|